Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | - AUD | -100.0% |
| 2023 | 1.47 Million AUD | -74.01% |
| 2022 | 5.66 Million AUD | 44.11% |
| 2021 | 3.93 Million AUD | 2324.97% |
| 2020 | -176.81 Thousand AUD | -132.82% |
| 2019 | 538.66 Thousand AUD | -55.87% |
| 2018 | 1.22 Million AUD | -3.85% |
| 2017 | 1.26 Million AUD | -24.74% |
| 2016 | 1.68 Million AUD | -57.11% |
| 2015 | 3.93 Million AUD | 13.83% |
| 2014 | 3.45 Million AUD | 31.6% |
| 2013 | 2.62 Million AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 30.83 Thousand AUD | -46.41% |
| 2024 FY | - AUD | -100.0% |
| 2024 Q4 | - AUD | 0.0% |
| 2024 Q2 | 30.83 Thousand AUD | 0.0% |
| 2023 Q1 | 668.13 Thousand AUD | -59.82% |
| 2023 FY | 1.47 Million AUD | -74.01% |
| 2023 Q4 | 57.54 Thousand AUD | 0.0% |
| 2023 Q3 | 57.54 Thousand AUD | -91.35% |
| 2023 Q2 | 664.84 Thousand AUD | -0.49% |
| 2022 FY | 5.66 Million AUD | 44.11% |
| 2022 Q3 | 1.65 Million AUD | 50.07% |
| 2022 Q4 | 1.66 Million AUD | 0.62% |
| 2022 Q2 | 1.1 Million AUD | 2.74% |
| 2022 Q1 | 1.07 Million AUD | -10.2% |
| 2021 Q4 | 1.19 Million AUD | -0.76% |
| 2021 Q1 | 734.05 Thousand AUD | 61.99% |
| 2021 FY | 3.93 Million AUD | 2324.97% |
| 2021 Q2 | 699.46 Thousand AUD | -4.71% |
| 2021 Q3 | 1.2 Million AUD | 71.94% |
| 2020 Q2 | 33.45 Thousand AUD | -94.92% |
| 2020 Q3 | 454.58 Thousand AUD | 1258.91% |
| 2020 Q4 | 453.15 Thousand AUD | -0.31% |
| 2020 FY | -176.81 Thousand AUD | -132.82% |
| 2020 Q1 | 658.59 Thousand AUD | 1524.74% |
| 2019 Q3 | 549.02 Thousand AUD | -47.07% |
| 2019 Q1 | 1.03 Million AUD | 24.22% |
| 2019 FY | 538.66 Thousand AUD | -55.87% |
| 2019 Q2 | 1.03 Million AUD | 0.0% |
| 2019 Q4 | 40.53 Thousand AUD | -92.62% |
| 2018 Q2 | 1.09 Million AUD | 0.0% |
| 2018 Q1 | 1.09 Million AUD | 36.46% |
| 2018 FY | 1.22 Million AUD | -3.85% |
| 2018 Q4 | 835.01 Thousand AUD | 0.0% |
| 2018 Q3 | 835.01 Thousand AUD | -23.58% |
| 2017 Q2 | 999.33 Thousand AUD | 0.0% |
| 2017 Q4 | 800.78 Thousand AUD | 0.0% |
| 2017 Q3 | 800.78 Thousand AUD | -19.87% |
| 2017 FY | 1.26 Million AUD | -24.74% |
| 2017 Q1 | 999.33 Thousand AUD | -5.66% |
| 2016 Q2 | 1.14 Million AUD | 0.0% |
| 2016 FY | 1.68 Million AUD | -57.11% |
| 2016 Q1 | 1.14 Million AUD | 18.15% |
| 2016 Q4 | 1.05 Million AUD | 0.0% |
| 2016 Q3 | 1.05 Million AUD | -7.27% |
| 2015 Q2 | 999.62 Thousand AUD | 0.0% |
| 2015 Q1 | 999.62 Thousand AUD | -1.47% |
| 2015 FY | 3.93 Million AUD | 13.83% |
| 2015 Q4 | 966.84 Thousand AUD | 0.0% |
| 2015 Q3 | 966.84 Thousand AUD | -3.28% |
| 2014 Q4 | 1.01 Million AUD | 0.0% |
| 2014 Q3 | 1.01 Million AUD | 42.3% |
| 2014 Q2 | 712.98 Thousand AUD | 0.0% |
| 2014 Q1 | 712.98 Thousand AUD | -4.7% |
| 2014 FY | 3.45 Million AUD | 31.6% |
| 2013 Q2 | 564.54 Thousand AUD | 0.0% |
| 2013 FY | 2.62 Million AUD | 0.0% |
| 2013 Q3 | 748.18 Thousand AUD | 32.53% |
| 2013 Q1 | 564.54 Thousand AUD | 0.0% |
| 2013 Q4 | 748.18 Thousand AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 100.0% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 100.0% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | 100.0% |
| Biome Australia Limited | 7.66 Million AUD | 100.0% |
| Patrys Limited | 1.39 Million AUD | 100.0% |
| Orthocell Limited | 3.68 Million AUD | 100.0% |
| Imugene Limited | -5.83 Million AUD | 100.0% |
| Noxopharm Limited | -534.81 Thousand AUD | 100.0% |
| PYC Therapeutics Limited | 22.05 Million AUD | 100.0% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 100.0% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 100.0% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 100.0% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 100.0% |
| CSL Limited | 15.28 Billion AUD | 100.0% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 100.0% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 100.0% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 100.0% |
| Starpharma Holdings Limited | 7.65 Million AUD | 100.0% |
| Nanollose Limited | -348.95 Thousand AUD | 100.0% |
| Memphasys Limited | 1606.00 AUD | 100.0% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 100.0% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 100.0% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 100.0% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 100.0% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 100.0% |
| Race Oncology Limited | 1.38 Million AUD | 100.0% |
| Nyrada Inc. | -5164.07 AUD | 100.0% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 100.0% |
| Dimerix Limited | 583.47 Thousand AUD | 100.0% |
| PharmAust Limited | -1641.00 AUD | 100.0% |
| Immutep Limited | 1.44 Million AUD | 100.0% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 100.0% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 100.0% |
| BTC Health Limited | 16.36 Thousand AUD | 100.0% |
| Acrux Limited | -1.28 Million AUD | 100.0% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 100.0% |
| Biotron Limited | -40.49 Thousand AUD | 100.0% |
| Tissue Repair Ltd | 150.51 Thousand AUD | 100.0% |
| AdAlta Limited | 1.5 Million AUD | 100.0% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 100.0% |
| AnteoTech Limited | 460.39 Thousand AUD | 100.0% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | 100.0% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 100.0% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 100.0% |
| Actinogen Medical Limited | 9.93 Million AUD | 100.0% |
| Immuron Limited | 3.33 Million AUD | 100.0% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 100.0% |